Single Oral Dose Comparative Bioavailability Study of Investigational Product in Healthy Human Subjects Under Fasting Conditions.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-01

Study Completion Date

2025-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The sponsor has developed new curcuminoid formulations with the expectation of enhanced bioavailability compared to existing benchmark products. This study aims to evaluate the comparative bioavailability and characterize the pharmacokinetic profile of the test formulations in comparison to the reference formulations in healthy adult subjects under fasting conditions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Comparative Pharmacokinetic Study to Evaluate the Ability of a New Formulation to Enhance Curcuminoids Bioavailability

NCT03621865

Healthy

COMPLETED NA

A Study to Compare the Pharmacokinetic Profile of a Proprietary Curcumin Forumulation to a Comparator Curcumin Product

NCT02474953

Healthy

COMPLETED PHASE1

Bioavailability Evaluation of CurQ+ Curcumin Formulation

NCT06177483

Bioavailability

COMPLETED NA

Comparison of Curcumin Bioavailability

NCT03530436

Safety After Oral Intake Pharmacokinetics After Oral Intake

COMPLETED NA

Evaluation of Increased Absorption of a Curcumin Emulsion (CurQ+) in Healthy Volunteers

NCT04103788

Bioavailability

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is an open-label, randomized, balanced, single oral dose, four-treatment, four-sequence, four-period, four-way cross-over comparative bioavailability trial designed to assess the bioavailability of different curcumin formulations in healthy adult volunteers under fasting conditions. A total of 24 subjects will be enrolled, each receiving four investigational products in a randomized sequence: non-formulated curcumin (90 mg, 1 capsule), Curcumin Dispersome formulation (600 mg; 2 x 300 mg capsules, each containing 90 mg curcumin), Turmipure Gold™ (300 mg, 1 capsule), and Qunol, Turmeric, Curcumin Complex, Extra Strength (1000 mg; 2 x 500 mg capsules). Each product will be administered as a single oral dose with 240 mL of water after at least 10 hours of fasting. Subjects will be housed in the clinical facility for at least 36 hours prior to dosing and remain for at least 24 hours post-dose during each period, with a minimum 7-day washout between periods. Safety will be monitored through clinical examination, vital signs, ECG, and laboratory assessments throughout the study. Blood samples for pharmacokinetic analysis will be collected at 13 time points in each period, and subjects will receive standardized turmeric-free meals and adhere to strict dietary and medication restrictions. The primary objective is to compare the bioavailability of the investigational products, with secondary objectives including the evaluation of safety and tolerability in the study population.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

An Open Label, Randomized, Balanced, Four-Treatment, Four-Sequence, Four-Period, Four-way cross-over, Single Oral dose comparative

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Curcumin Dispersome formulation

75% BLG (600 mg (2 capsules of 300 mg each, containing 90 mg curcumin per capsule

Group Type EXPERIMENTAL

Curcumin Dispersome formulation

Intervention Type OTHER

75% BLG (600 mg (2 capsules of 300 mg each, containing 90 mg curcumin per capsule

Non-formulated Curcumin

dose: 90 mg, 1 capsule

Group Type EXPERIMENTAL

Non-formulated Curcumin

Intervention Type OTHER

dose: 90 mg, 1 capsule

Benchmark Formulation 1 - Turmipure Gold™

recommended daily dose: 300 mg, 1 capsule

Group Type ACTIVE_COMPARATOR

Benchmark Formulation 1 - Turmipure Gold™

Intervention Type OTHER

recommended daily dose: 300 mg, 1 capsule

Benchmark Formulation 2 - Qunol, Turmeric, Curcumin Complex, Extra Strength

recommended daily dose: 1000 mg, 2 capsules of 500 mg each

Group Type ACTIVE_COMPARATOR

Benchmark Formulation 2 - Qunol, Turmeric, Curcumin Complex, Extra Strength

Intervention Type OTHER

recommended daily dose: 1000 mg, 2 capsules of 500 mg each

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Curcumin Dispersome formulation

75% BLG (600 mg (2 capsules of 300 mg each, containing 90 mg curcumin per capsule

Intervention Type OTHER

Non-formulated Curcumin

dose: 90 mg, 1 capsule

Intervention Type OTHER

Benchmark Formulation 1 - Turmipure Gold™

recommended daily dose: 300 mg, 1 capsule

Intervention Type OTHER

Benchmark Formulation 2 - Qunol, Turmeric, Curcumin Complex, Extra Strength

recommended daily dose: 1000 mg, 2 capsules of 500 mg each

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 9.5.1 Able and willing to participate in the study by complying with the protocol procedures as evidenced by a dated and signed informed consent form 9.5.2 Age greater than equal to 18 less than equal to 45 years. 9.5.3 Willing to consume the study product and donate blood. 9.5.4 BMI from 18.5 to 29.9 kg/m². 9.5.5 Subject with normal health as determined by personal medical and medication history, clinical examination and laboratory examinations within the clinically acceptable limits.

9.5.6 Subjects having vital parameters (blood pressure, body temperature, pulse rate and respiratory rate) within acceptable limits.

9.5.7 Non-smokers or mild/moderate smokers with not more than 10 bidis/cigarettes/pipes per day, and willing to abstain from smoking or chewing any tobacco containing products at least 72.00 hours prior to check-in and throughout the sampling points.

9.5.8 Agreeing not to consume food, drink and condiment containing curcumin (e.g. curry), or other curcuminoids (DMC, BDMC) for the whole duration of the study (36 hours pre-dose to 24 hours post-dose in each period).

9.5.9 Good general and mental health in the opinion of the investigator: no clinically significant or relevant abnormalities upon review of medical history or following a physical examination prior to check-in.

9.5.10 If study volunteer is a female and is of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator, such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence Or She is surgically sterile (had a bilateral tubal ligation, bilateral oophorectomy with or without a hysterectomy and an absence of bleeding for at least 06 months).

Exclusion Criteria

* 9.6.1 Any medical or surgical conditions, which might significantly interfere with the functioning of gastrointestinal tract or may affect absorption of IP and blood forming organ.

9.6.2 Significant history or current evidence of malignancy or chronic - infectious, cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological, metabolic (endocrine), hematological, gastrointestinal, immunological or psychiatric disease or organ dysfunction.

9.6.3 Any major illness or hospitalization within 90 days prior to first admission to the study.

9.6.4 Use of any depot injection or an implant of any drug within 3 months prior to check-in and throughout the study.

9.6.5 Use of any prescribed medication or OTC (including herbal drugs and vitamin supplements) within 14 days prior to check-in and throughout the study.

9.6.6 Use of botanical dietary supplements during the study or within three months prior to check-in.

9.6.7 Difficulty in swallowing capsules. 9.6.8 History or presence of alcohol abuse in the past one year \[Alcohol abuse will be defined as greater than 14 drinks per week (1 drink equal to 360 mL beer, 150 mL wine, or 45 mL hard liquor)\].

9.6.9 Consumption of alcoholic products within 24.00 hours prior to check-in in each study period and throughout sampling time points.

9.6.10 Positive alcohol breath or urine drug of abuse test during check-in on each study period.

9.6.11 Consumption of xanthine's or its derivative containing food or beverages (e.g. chocolates, tea, coffee or cola drinks) within 48.00 hours prior to check-in and throughout sampling time points.

9.6.12 Consumption of grapefruit or its juice within 72.00 hours prior to check-in in each period and throughout sampling time points.

9.6.13 History of allergy or hypersensitivity intolerance to turmeric or curcumin.

9.6.14 Individuals who, in the opinion of the investigator, are unlikely to be able to comply with the study.

9.6.15 Irritable bowel syndrome. 9.6.16 Current disease states that are contraindicated with dietary supplementation: chronic diarrhea, constipation or abdominal pain, chronic laxatives use.

9.6.17 Pathology which could affect the study results or expose the subject to an additional risk according to the investigator.

9.6.18 Recent gastroenteritis or food borne illness such as confirmed food poisoning (less than 1 month).

9.6.19 Blood donation within 90 Days prior to the initial visit or intending to donate within the next 90 Days.

9.6.20 Low venous capital not allowing blood kinetic sampling. 9.6.21 Known or suspected food allergy, intolerance, or hypersensitivity to any of the study product ingredients and/or of the standard meals (gluten intolerance, celiac disease, etc.) 9.6.22 Chronic drug treatment (for example anticoagulant, antihypertensive medication, thyroid treatment, asthma treatment, anxiolytic, antidepressant, lipid-lowering treatment, corticosteroids, phlebotonic, veino-tonic, drug with impact on blood circulation) excluding oral and local contraceptives.

9.6.23 Currently taking (or during the past 3 months) any botanical dietary supplement.

9.6.24 History of anorexia nervosa, bulimia, or significant eating disorders according to the investigator.

9.6.25 Participation in another clinical trial 90 days prior to check-in period I of this study.

9.6.26 Presenting a psychological or linguistic incapability to sign the informed consent.

9.6.27 Female volunteer who has used implanted or injected hormonal contraceptives anytime during the 06 months prior to check-in or used hormonal contraceptives within 14 days before check-in

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes